Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.49 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3161256 | 0.87 | NPBWR1 (0.49) | GPR119NPBWR1MCHR1KMT2AMEN1 | |
| SCHEMBL3164057 | 0.86 | NPBWR1 (0.48) | GPR119NPBWR1MCHR1KMT2AMEN1 | |
| SCHEMBL3168196 | 0.85 | NPBWR1 (0.48) | GPR119NPBWR1MCHR1KMT2AMEN1 | |
| SCHEMBL7354087 | 0.81 | PDE4B (0.53) | GPR119NPBWR1MCHR1PDE4D | |
| SCHEMBL15013973 | 0.79 | GPR119 (0.49) | GPR119NPBWR1MCHR1KMT2AMEN1 | |
| SCHEMBL3160552 | 0.79 | GPR119 (0.54) | GPR119KMT2AMEN1SMN1; SMN2PDE4D | |
| SCHEMBL3164585 | 0.77 | GPR119 (0.51) | GPR119NPBWR1MCHR1KMT2AMEN1 | |
| SCHEMBL7406884 | 0.77 | GPR119 (0.56) | GPR119KMT2AMEN1HPGDHSD17B10 | |
| SCHEMBL3165306 | 0.77 | GPR119 (0.48) | GPR119NPBWR1MCHR1KMT2AMEN1 | |
| SCHEMBL23301265 | 0.77 | GPR119 (0.58) | GPR119KMT2AMEN1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700628-B2 | Aromatic ether derivatives useful as thrombin inhibitors | ELI LILLY AND COMPANY (US) | 2010-04-20 | — | — | US | disclosed |
| EP-1817287-B1 | AROMATIC ETHER DERIVATIVES USEFUL AS THROMBIN INHIBITORS | LILLY CO ELI (US) | 2010-02-10 | — | — | EP | disclosed |
| US-20090227566-A1 | AROMATIC ETHER DERIVATIVES USEFUL AS THROMBIN INHIBITORS | ELI LILLY AND COMPANY | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227566-A1 | AROMATIC ETHER DERIVATIVES USEFUL AS THROMBIN INHIBITORS | TFPI, F2, F11 | GPR119 2215/4885NPBWR1 2758/4885MCHR1 4246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.